Atamyo Therapeutics

Executive Summary

Atamyo Therapeutics is a French biotechnology company founded in 2019 as a spin-off from Genethon, dedicated to developing next-generation gene therapies for neuromuscular diseases, specifically limb-girdle muscular dystrophies (LGMDs). The company leverages over 25 years of foundational research to create best-in-class treatments with enhanced safety and efficacy, aiming to provide life-long solutions for patients. Currently in Phase 1 clinical development, Atamyo's lead program targets LGMD2I/R9, a severe form of muscular dystrophy caused by mutations in the FKRP gene. The company's proprietary AAV-based gene therapy platform is designed to deliver durable expression of the therapeutic transgene while minimizing immunogenicity. With a strong scientific foundation and an experienced management team, Atamyo is well-positioned to address significant unmet needs in the LGMD space, where few effective treatments exist. The biotech has garnered interest from investors and collaborators, though total funding details remain undisclosed. As the company progresses its pipeline, upcoming data readouts and regulatory milestones will be critical for advancing its therapies toward registration and commercialization.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 interim data readout for lead gene therapy candidate AT-GTX-001 in LGMD2I/R965% success
• Q1 2027Initiation of Phase 1/2 trial for second program targeting LGMD2A (calpainopathy)70% success
• Q3 2026Regulatory update on orphan drug designation or fast track status from FDA/EMA80% success